Metopimazine
Clinical data | |
---|---|
Trade names | Vogalen, Vogalene |
Other names | EXP-999; RP-9965; NG-101 |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Metopimazine (
Metopimazine has
Medical uses
Metopimazine is an approved
Adverse effects
Generally, studies in chemotherapy-induced nausea and vomiting suggest that doses of metopimazine higher than approved for common nausea and vomiting conditions tend to be more
In aMechanism of action
Metopimazine, a phenothiazine derivative, is a potent D2/D3 dopamine receptor antagonist. Metopimazine has also shown adrenergic alpha1, histamine H1, serotonin 5HT2a antagonism.[10]
Pharmacokinetics
The pharmacokinetics (PK) profile of metopimazine has been reported as comparable between adults and children. The maximum plasma concentration (Cmax) of metopimazine is reached approximately 60 minutes after oral administration, and the elimination half-life is approximately two hours.
The bioavailability of metopimazine in humans is low. A 10 mg dose of metopimazine was reported to have an absolute bioavailability under 20%.[26]
Research
Metopimazine mesylate (NG101), a novel formulation of metopimazine, is under clinical development for idiopathic gastroparesis in the United States.[27] Gastroparesis is a debilitating chronic gastrointestinal disorder characterized by delayed gastric emptying without evidence of mechanical obstruction. Symptoms include nausea, vomiting, early satiety, postprandial fullness, bloating, and upper abdominal pain.[28][29][30]
Synthesis
For the first step, 2-Methylthiophenothiazine [7643-08-5] (1) is protected by sequential reaction with sodium amide and acetic anhydride to give 1-[2-(Methylthio)-10H-phenothiazin-10-yl]ethanone [23503-69-7] (2). Oxidation with peracid proceeds preferentially on the more electron-rich alkyl thioether to give the sulfone. Upon hydrolysis of the acetate this affords 2-(methylsulfonyl)-10h-phenothiazine [23503-68-6] (3). Alkylation with 1-Bromo-3-chloropropane (4) gives 10-(3-chloropropyl)-2-methylsulfonylphenothiazine [40051-30-7] (5). Alkylation with piperidine-4-carboxamide (Isonipecotamide) [39546-32-2] (6) affords metopimazine (7).
References
- OCLC 1058412474.
- ^ ISBN 978-3-88763-075-1.
- OCLC 1243535030.
- PMID 9777292.
- ^ PMID 33471485.
- ^ a b "Metopimazine - Neurogastrx - AdisInsight".
- S2CID 220909387.
- ^ "Vogalene®". www.rxreasoner.com.
- ^ "Accueil - ANSM". ansm.sante.fr (in French). Retrieved 26 March 2023.
- ^ S2CID 76202219.
- ^ "Vogalib". www.rxreasoner.com.
- PMID 34292534.
- PMID 5596819.
- PMID 5797645.
- PMID 5314918.
- PMID 4944444.
- PMID 4261213.
- PMID 38705.
- ^ PMID 9193370.
- PMID 9358940.
- PMID 11283143.
- S2CID 24370010.
- S2CID 8708071.
- PMID 26171218.
- PMID 34918875.
- ^ PMID 2206785.
- ^ "A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study, of the Safety and Efficacy of NG101 Administered Orally to Patients With Gastroparesis". clinicaltrials.gov. 4 November 2022.
- PMID 35926490.
- .
- PMID 25874755.
- ^ DE 1092476, Jacob RM, Robert JG, issued 1960, assigned to Rhone Poulenc SA.
- S2CID 102478746.
External links
- "Metopimazine". AdisInsight. Springer Nature Switzerland AG.